Advances in oral therapy for multiple myeloma

Lancet Oncology

Volumn 7, Issue 4, 2006, Pages 316-325

  Morgan, Gareth J ^a,b   Krishnan, Biju ^a   Jenner, Matthew ^a   Davies, Faith E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BORTEZOMIB; CARMUSTINE; CHIR 258; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GLUCOCORTICOID; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; LONAFARNIB; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; NVP ADW 742; PAMIDRONIC ACID; PLACEBO; PREDNISONE; ROSCOVITINE; SCIO 469; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VATALANIB; ENZYME INHIBITOR; IMMUNOLOGIC FACTOR; VASCULOTROPIN A;

ANEMIA; ANTINEOPLASTIC ACTIVITY; AUTOTRANSPLANTATION; BLOOD TOXICITY; BONE MARROW; BONE MARROW SUPPRESSION; BRADYCARDIA; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DEHYDRATION; DEPRESSION; DIARRHEA; DRUG ERUPTION; DRUG MEGADOSE; DRUG PREFERENCE; DRUG TARGETING; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HEARING LOSS; HEART ARRHYTHMIA; HUMAN; ILEUS; INDIGESTION; INFECTION; INNER EAR DISEASE; LIFESPAN; LIVER DYSFUNCTION; LUNG EMBOLISM; MALAISE; MULTIPLE MYELOMA; MUSCLE CRAMP; MYELOMA CELL; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEDATION; SIDE EFFECT; SINUS BRADYCARDIA; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SYNCOPE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; VENOUS THROMBOEMBOLISM; VERTIGO; DRUG ANTAGONISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33645756315     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70657-X     Document Type: Review

References (78)

1. SA Payne A study of quality of life in cancer patients receiving palliative chemotherapy Soc Sci Med 35 1992 1505-1509
2. A Coates S Abraham SB Kaye et al. On the receiving end-patient perception of the side-effects of cancer chemotherapy Eur J Cancer Clin Oncol 19 1983 203-208
3. E Van Cutsem PM Hoff P Harper et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised, phase III trials Br J Cancer 90 2004 1190-1197
4. S Ward E Kaltenthaler J Cowan N Brewer Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: Systematic review and economic evaluation Health Technol Assess 7 2003 1-93
5. G Liu E Franssen MI Fitch E Warner Patient preferences for oral versus intravenous palliative chemotherapy J Clin Oncol 15 1997 110-115
6. M Borner W Scheithauer C Twelves et al. Answering patients' needs: Oral alternatives to intravenous therapy Oncologist 6 2001 12-16
7. RA Kyle SV Rajkumar Multiple myeloma N Engl J Med 351 2004 1860-1873
8. Myeloma Trialists' Collaborative Group Combination chemotherapy versus melphalan plus prednisone as treatmentfor multiple myeloma: An overview of 6,633 patients from 27 randomized trials J Clin Oncol 16 1998 3832-3842
9. T Hideshima KC Anderson Molecular mechanisms of novel therapeutic approaches for multiple myeloma Nat Rev Cancer 2 2002 927-937
10. R Alexanian B Barlogie S Tucker VAD-based regimens as primary treatment for multiple myeloma Am J Hematol 33 1990 86-89
11. NC Munshi Recent advances in the management of multiple myeloma Semin Hematol 41 2004 21-26
12. J-L Harousseau J Shaughnessy Jr P Richardson Multiple myeloma Hematology (Am Soc Hematol Educ Program) 2004 237-256
13. ICM MacLennan C Chapman J Dunn K Kelly Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults Lancet 339 1992 200-205
14. MT Drayson The value of anthracycline sparing by the use of weekly cyclophosphamide after induction with the ABCM regimen: Results of the VIIIth MRC Myeloma trial 2003 Proceedings of the IXth International Myeloma Workshop Salamanka, Spain OP225
15. R Alexanian MA Dimopoulos K Delasalle B Barlogie Primary dexamethasone treatment of multiple myeloma Blood 80 1992 887-890
16. R Alexanian B Barlogie D Dixon High-dose glucocorticoid treatment of resistant myeloma Ann Intern Med 105 1986 8-11
17. WR Friedenberg RA Kyle WH Knospe et al. High-dose dexamethasone for refractory or relapsing multiple myeloma Am J Hematol 36 1991 171-175
18. G Cook RE Clark TCM Morris et. al. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma Br J Haematol 126 2004 792-798
19. S Singhal J Mehta R Desikan et al. Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1999 1565-1571
20. B Barlogie R Desikan P Eddlemon et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients Blood 98 2001 492-494
21. P Richardson R Schlossman S Jagannath et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: Results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity Mayo Clin Proc 79 2004 875-882
22. S Kumar MA Gertz A Dispenzieri et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma Mayo Clin Proc 78 2003 34-39
23. M Hus A Dmoszynska M Soroka-Wojtaszko et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients Haematologica 86 2001 404-408
24. SV Rajkumar MA Gertz MQ Lacy et al. Thalidomide as initial therapy for early-stage myeloma Leukemia 17 2003 775-779
25. D Weber K Rankin M Gavino et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma J Clin Oncol 21 2003 16-19
26. JB Bartlett K Dredge AG Dalgleish The evolution of thalidomide and its IMiD derivatives as anticancer agents Nat Rev Cancer 4 2004 314-322
27. RJ D'Amato MS Loughnan E Flynn J Folkman Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci USA 91 1994 4082-4085
28. SK Teo DI Stirling JB Zeldis Thalidomide as a novel therapeutic agent: new uses for an old product Drug Discov Today 10 2005 107-114
29. FE Davies N Raje T Hideshima et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma Blood 98 2001 210-216
30. SV Rajkumar S Hayman MA Gertz et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma J Clin Oncol 20 2002 4319-4323
31. SV Rajkumar E Blood D Vesole et al. Phase III trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol 24 2006 431-436
32. A Palumbo A Bertola P Falco et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma Hematol J 5 2004 318-324
33. A Anagnostopoulos D Weber K Rankin et al. Thalidomide and dexamethasone for resistant multiple myeloma Br J Haematol 121 2003 768-771
34. P Bernardeschi P Dentico S Rossi et al. Chemoresistant myeloma: Phase II clinical study with low-dose thalidomide plus high-dose dexamethasone J Chemother 16 suppl 5 2004 90-93
35. A Palumbo L Giaccone A Bertola et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma Haematologica 86 2001 399-403
36. M Cavo E Zamagni P Tosi et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma Haematologica 89 2004 826-831
37. M Cavo E Zamagni P Tosi et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma Blood 106 2005 35-39
38. R Alexanian D Weber S Giralt K Delasalle Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy Ann Oncol 13 2002 1116-1119
39. CD Williams JL Byrne G Sidra et al. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone achieves a high response rate in patients with newly diagnosed, VAD-refractory and relapsed myeloma Blood 104 2004 419 (abstr)
40. C Kyriakou K Thomson S D'Sa et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma Br J Haematol 129 2005 763-770
41. MA Dimopoulos G Hamilos A Zomas et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: An oral regimen for previously treated patients with multiple myeloma Hematol J 5 2004 112-117
42. R Garcia-Sanz JR Gonzalez-Porras JM Hernandez et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma Leukemia 18 2004 856-863
43. A Palumbo A Bertola P Musto et al. A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): An interim analysis Blood 104 2004 63 (abstr)
44. M Attal J-L Harousseau S Leyvraz et al. Maintenance treatment with thalidomide after autologous transplantation for myeloma: First analysis of a prospective randomized study of the Intergroupe Francophone du Myeloma (IFM 99 02) Blood 104 2004 155 (abstr)
45. IM Ghobrial SV Rajkumar Management of thalidomide toxicity J Support Oncol 1 2003 194-205
46. P Tosi E Zamagni C Cellini et al. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma Eur J Haematol 74 2005 212-216
47. M Zangari E Anaissie B Barlogie et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy Blood 98 2001 1614-1615
48. MC Minnema I Breitkreutz JJ Auwerda et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy Leukemia 18 2004 2044-2046
49. MA Dimopoulos P Repoussis E Terpos et al. Primary treatment with pulsed melphalan, dexamethasone, thalidomide (MDT) for symptomatic patients with multiple myeloma >75 years of age Blood 104 2004 414 (abstr)
50. M Zangari B Barlogie E Anaissie et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: Effects of prophylactic and therapeutic anticoagulation Br J Haematol 126 2004 715-721
51. KC Anderson The role of immunomodulatory drugs in multiple myeloma Semin Hematol 40 suppl 4 2003 23-32
52. S Lentzsch R LeBlanc K Podar et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo Leukemia 17 2003 41-44
53. N Mitsiades CS Mitsiades V Poulaki et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications Blood 99 2002 4525-4530
54. PG Richardson RL Schlossman E Weller et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma Blood 100 2002 3063-3067
55. M Zangari G Tricot J Zeldis et al. Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT) Blood 98 2001 775 (abstr)
56. PG Richardson S Jagannath R Schlossman et al. A multi-center, randomized, phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for treatment of relapsed or refractory multiple myeloma (MM) Blood 102 2003 235 (abstr)
57. SV Rajkumar SR hayman MO lacy et al. Combination therapy with CC-5013 (lenalidomide; Revlimid) plus dexamethasone (Rev/Dex) for newly diagnosed myeloma (MM) Blood 104 2004 98 (abstr)
58. D Weber Lenalidomide and other IMiDs. Proceedings of the 10th International Multiple Myeloma Workshop, Sydney, Australia Haematologica s1 2005 PL5.02
59. A Neri JP Murphy L Cro et al. Ras oncogene mutation in multiple myeloma J Exp Med 170 1989 1715-1725
60. M Alsina R Fonseca EF Wilson et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma Blood 103 2004 3271-3277
61. CS Mitsiades NS Mitsiades CJ McMullan et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications Proc Natl Acad Sci USA 101 2004 540-545
62. L Catley E Weisberg YT Tai et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma Blood 102 2003 2615-2622
63. SB Khan T Maududi K Barton et al. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma Br J Haematol 125 2004 156-161
64. P Richardson RL Schlossman CS Mitsiades et al. Phase I clinical trial of oral administration of the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with relapsed / refractory multiple myeloma (MM) Blood 104 2004 420 (abstr)
65. K Podar YT Tai FE Davies S Lentzsch et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration Blood 98 2001 428-435
66. B Lin K Podar D Gupta et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment Cancer Res 62 2002 5019-5026
67. T Hideshima M Akiyama T Hayashi et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu Blood 101 2003 703-705
68. N Raje S Kumar T Hideshima et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma Blood 106 2005 1042-1047
69. DE MacCallum J Melville S Frame et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1 Cancer Res 65 2005 5399-5407
70. YT Tai K Podar L Catley et al. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of b1-integrin and phosphatidylinositol 3β-kinase/AKT signaling Cancer Res 63 2003 5850-5858
71. CS Mitsiades NS Mitsiades CJ McMullan et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors Cancer Cell 5 2004 221-230
72. S Trudel ZH Li E Wei et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma Blood 105 2005 2941-2948
73. PG Richardson P Sonneveld MW Schuster et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2005 2487-2498
74. PG Richardson T Hideshima C Mitsiades K Anderson Proteasome inhibition in hematologic malignancies Ann Med 36 2004 304-314
75. N Mitsiades CS Mitsiades PG Richardson et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications Blood 101 2003 2377-2380
76. P Workman Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone Cancer Lett 206 2004 149-157
77. CS Mitsiades N Mitsiades M Rooney et al. Anti-tumor activity of KOS-953, a cremophor-based formulation of the hsp90 inhibitor 17-AAG Blood 104 2005 2404
78. C Mitsiades A Chanan-Khan M Alsina et al. Phase 1 trial of 17-AAG in patients with relapsed and refractory multiple myeloma (MM) J Clin Oncol 23 2005 3056